These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30775977)

  • 1. The Alz-tau Biomarker for Alzheimer's Disease: Study in a Caucasian Population.
    Guzmán-Martínez L; Tapia JP; Farías GA; González A; Estrella M; Maccioni RB
    J Alzheimers Dis; 2019; 67(4):1181-1186. PubMed ID: 30775977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease.
    Slachevsky A; Guzmán-Martínez L; Delgado C; Reyes P; Farías GA; Muñoz-Neira C; Bravo E; Farías M; Flores P; Garrido C; Becker JT; López OL; Maccioni RB
    J Alzheimers Dis; 2017; 55(4):1595-1603. PubMed ID: 27911301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Tau Variants Detected by a Novel Anti-Tau Monoclonal Antibody: A Potential Biomarker for Alzheimer's Disease.
    González A; Guzmán-Martínez L; Maccioni RB
    J Alzheimers Dis; 2020; 77(2):877-883. PubMed ID: 32741827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet Amyloid-β Protein Precursor (AβPP) Ratio and Phosphorylated Tau as Promising Indicators for Early Alzheimer's Disease.
    Shi Y; Gu L; Wang Q; Gao L; Zhu J; Lu X; Zhou F; Zhu D; Zhang H; Xie C; Zhang Z
    J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):664-670. PubMed ID: 31336382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human platelets tau: a potential peripheral marker for Alzheimer's disease.
    Neumann K; Farías G; Slachevsky A; Perez P; Maccioni RB
    J Alzheimers Dis; 2011; 25(1):103-9. PubMed ID: 21368381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet Tau Protein as a Potential Peripheral Biomarker in Alzheimer's Disease: An Explorative Study.
    Mukaetova-Ladinska EB; Abdell-All Z; Andrade J; da Silva JA; Boksha I; Burbaeva G; Kalaria RN; T O Brien J
    Curr Alzheimer Res; 2018; 15(9):800-808. PubMed ID: 29623842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.
    Abe K; Shang J; Shi X; Yamashita T; Hishikawa N; Takemoto M; Morihara R; Nakano Y; Ohta Y; Deguchi K; Ikeda M; Ikeda Y; Okamoto K; Shoji M; Takatama M; Kojo M; Kuroda T; Ono K; Kimura N; Matsubara E; Osakada Y; Wakutani Y; Takao Y; Higashi Y; Asada K; Senga T; Lee LJ; Tanaka K
    J Alzheimers Dis; 2020; 73(1):217-227. PubMed ID: 31771070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression.
    Nam E; Lee YB; Moon C; Chang KA
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
    Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
    Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
    Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects.
    Tsolaki M; Sakka V; Gerasimou G; Dimacopoulos N; Chatzizisi O; Fountoulakis KN; Kyriazis G; Papanastasiou J; Kazis A
    Am J Alzheimers Dis Other Demen; 2001; 16(1):21-31. PubMed ID: 11416945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort.
    Radanovic M; Oshiro CA; Freitas TQ; Talib LL; Forlenza OV
    Braz J Psychiatry; 2019; 41(6):479-484. PubMed ID: 31166546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.